Mometasone Furoate (Nasal Spray)

Indications

Mometasone Furoate Nasal Spray is indicated for the treatment of the nasal symptoms of seasonal and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older. It is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and adolescent patients 12 years and older. It is also indicated for the treatment of nasal polyps in patients 18 years and older.

Pharmacology

Mometasone Furoate monohydrate is a corticosteroid demonstrating antiinflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (eg, histamines, eicosanoids, leukotrienes, and cytokines) involved in inflammation. Protein binding for Mometasone Furoate was reported to be 98% to 99% in concentration range of 5 to 500 ng/mL.The effective plasma elimination half life of Mometasone Furoate is 5.8 hours.

Dosage And Administration

Allergic Rhinitis-

  • Adults and Children 12 Years of Age and Older: The recommended dose for prophylaxis and treatment of the nasal symptoms of seasonal allergic rhinitis and treatment of the nasal symptoms of perennial allergic rhinitis is two sprays (50 mcg of Mometasone Furoate in each spray) in each nostril once daily (total daily dose of 100 mcg). In patients with a known seasonal allergen that precipitates nasal symptoms of seasonal allergic rhinitis, prophylaxis with Mometasone Nasal Spray, 50 mcg (200 mcg/day) isrecommended 2 to 4 weeks prior to the anticipated start of the pollen season.
  • Children 2 to 11 Years of Age: The recommended dose fortreatment ofthe nasalsymptoms of seasonal and perennial allergic rhinitis is one spray (50 mcg of Mometasone Furoate in each spray) in each nostril once daily (total daily dose of 100 mcg).

Nasal Polyps Adults-

  • 18 years of Age and Older: The recommended dose for nasal polyps is two sprays (50 mcg of Mometasone Furoate in each spray) in each nostril twice daily (total daily dose of 400 mcg). A dose of two sprays (50 mcg of mometasone furoate in each spray) in each nostril once daily (total daily dose of 200 mcg) is also effective in some patients.

 

Administration

How to use the Nasal Spray-

  • Shake the bottle gently and remove the dust cover.
  • Hold the spray with your forefinger and middle finger on either side of the nozzle and your thumb underneath the bottle. Press down until a fine spray appears. If using for the first time or if you have not used it for a week or more, press the nasal applicator several times until a fine moist comes out from the container.
  • Gently blow the nose to clear the nostrils.
  • Close one nostril and carefully insert the nasal applicator into the open nostril. Tilt your head forward slightly and keep the spray upright. Breathe in through your nose and while breathing in, press the white-collar of nasal applicator firmly down once to release a spray.
  • Breathe out through your mouth.
  • Repeat the above steps in the same/ other nostril for consecutive doses.

Cleaning: The nasal spray should be cleaned at least once a week. The procedures are as follows-

  • Remove the dust cover.
  • Gently pull off the nasal applicator.
  • Wash the applicator and dust cover in warm water.
  • Shake off the excess water and leave to dry in a normal place. Avoid to apply additional heat.
  • Gently push the applicator back on the top of the bottle and re-fix the dust cover.

Interaction

There are no drug interactions of note with Mometasone Furoate.

Contraindications

Hypersensitivity to any of the ingredients of this preparation contraindicates its use.

Side Effects

Side effects are generally mild and included headache, viral infection, sore throat, nosebleeds, and coughing.

Pregnancy And Lactation

There are no adequate and well-controlled studies in pregnant women. Mometasone Furoate, like other corticosteroids, should be used during pregnancy only if the potential benefits justify the potential risk to the fetus. It is not known if Mometasone Furoate is excreted in human milk. Because other corticosteroids are excreted in human milk, caution should be used when Mometasone is administered to nursing women.

Precautions And Warnings

While using nasal corticosteroids, caution is required in patients with active or dormant tuberculous infection, or in untreated fungal, bacterial, systemic viral infections, or ocular herpes simplex.

Overdose Effects

There are no data available on the effects of acute or chronic overdosage with Mometasone. Because of low systemic bioavailability, and an absence of acute drugrelated systemic findings in clinical studies, overdose is unlikely to require any therapy other than observation.

Therapeutic Class

Nasal Steroid Preparations.

Storage Conditions

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Available Brand Names